Sørensen H T, Olsen J H, Mellemkjaer L, Marie A, Steffensen F H, McLaughlin J K, Baron J A
Department of Medicine V, Aarhus University Hospital, Aarhus, Denmark.
Cancer. 2000 Jul 1;89(1):165-70. doi: 10.1002/1097-0142(20000701)89:1<165::aid-cncr21>3.0.co;2-g.
Data regarding the association between the use of calcium channel blockers and cancer risk have been conflicting. In the current study, the authors examined the cancer risk and mortality in users of calcium channel blockers in North Jutland County, Denmark.
The authors conducted a cohort study using record linkage between a population-based prescription database, the Danish Cancer Registry, and the Danish Death Registry including 23, 167 users of calcium channel blockers who received >/=2 prescriptions between January 1, 1989 and December 31, 1995. The authors calculated the standardized incidence ratios and standard mortality ratios for cancer, along with corresponding 95% confidence intervals (95% CI).
Overall, 967 incident cases of cancer occurred, resulting in a standardized incidence ratio of 1.04 (95% CI, 0.98-1.11). There was a slightly elevated nonsignificant risk of tobacco-related cancer. No increased risk of breast or colon carcinoma was observed. The cancer mortality was close to that expected in the background population (standardized mortality ratio of 0.97; 95% CI, 0.89-1.04).
This large-scale, population-based cohort study adds to the increasing evidence indicating no substantial association between the use of calcium channel blockers and the incidence rate of cancer or cancer mortality.
关于使用钙通道阻滞剂与癌症风险之间关联的数据一直存在矛盾。在本研究中，作者调查了丹麦北日德兰郡使用钙通道阻滞剂者的癌症风险和死亡率。
作者进行了一项队列研究，利用基于人群的处方数据库、丹麦癌症登记处和丹麦死亡登记处之间的记录链接，纳入了1989年1月1日至1995年12月31日期间接受≥2次处方的23167名钙通道阻滞剂使用者。作者计算了癌症的标准化发病率和标准化死亡率，以及相应的95%置信区间（95%CI）。
总体而言，共发生967例癌症病例，标准化发病率为1.04（95%CI，0.98 - 1.11）。与烟草相关癌症的风险略有升高，但无统计学意义。未观察到乳腺癌或结肠癌风险增加。癌症死亡率接近背景人群预期水平（标准化死亡率为0.97；95%CI，0.89 - 1.04）。
这项大规模的基于人群的队列研究进一步增加了证据，表明使用钙通道阻滞剂与癌症发病率或癌症死亡率之间无实质性关联。
